Literature DB >> 1280224

Relative roles of decay-accelerating factor, membrane cofactor protein, and CD59 in the protection of human endothelial cells against complement-mediated lysis.

R A Brooimans1, P A van Wieringen, L A van Es, M R Daha.   

Abstract

Human umbilical vein endothelial cells (HUVEC) were found by Western blot analysis to express three membrane-bound C regulatory proteins, decay-accelerating factor (DAF), membrane cofactor protein (MCP) and CD59. DAF was detected on sodium dodecyl sulfate-polyacrylamide gel electrophoresis as a 70-kDa molecule under nonreducing conditions in 2% deoxycholate extracts of HUVEC, MCP as a 63-kDa protein and CD59 as a 20-kDa molecule. Northern blot analysis revealed the presence of two species of mRNA expressed in HUVEC, which hybridized to a cDNA probe specific for DAF, with sizes of about 2.0 kb and 2.7 kb. MCP mRNA was detected at 4.2 kb and a CD59 cDNA probe hybridized with three mRNA species with sizes of about 800, 1400 and 2000 bp. DAF and CD59 were released from the surface of HUVEC by phosphatidylinositol-phospholipase C, demonstrating that both are attached to the cell membrane by means of a glycolipid anchor. The relative contribution of DAF, MCP and CD59 in regulating the sensitivity to lysis of HUVEC by autologous complement was determined by incubation of sensitized endothelial cells with F(ab')2 fragments of polyclonal antibodies raised against these proteins. The susceptibility of sensitized cells to lysis by homologous complement was markedly increased in the presence of F(ab')2 anti-CD59 and to a lesser, but significant, extent in the presence of F(ab')2 anti-DAF. F(ab')2 anti-MCP did not significantly alter the susceptibility of HUVEC to complement-mediated lysis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1280224     DOI: 10.1002/eji.1830221216

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  10 in total

1.  Establishment of a human DAF/HRF20 double transgenic mouse line is not sufficient to suppress hyperacute rejection.

Authors:  C Koike; K Isobe; I Nakashima; H Okada; S Hayashi; I Yokoyama; H Takagi
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

Review 2.  Role of complement and complement regulatory proteins in the complications of diabetes.

Authors:  Pamela Ghosh; Rupam Sahoo; Anand Vaidya; Michael Chorev; Jose A Halperin
Journal:  Endocr Rev       Date:  2015-04-10       Impact factor: 19.871

3.  Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59.

Authors:  D L Bodian; S J Davis; B P Morgan; N K Rushmere
Journal:  J Exp Med       Date:  1997-02-03       Impact factor: 14.307

4.  Protection against hyperacute xenograft rejection of transgenic rat hearts expressing human decay accelerating factor (DAF) transplanted into primates.

Authors:  B Charreau; S Ménoret; L Tesson; A Azimzadeh; M Audet; P Wolf; R Marquet; C Verbakel; J Ijzermans; P Cowan; M Pearse; A d'Apice; J P Soulillou; I Anegon
Journal:  Mol Med       Date:  1999-09       Impact factor: 6.354

5.  Human and rodent decay-accelerating factors (CD55) are not species restricted in their complement-inhibiting activities.

Authors:  C L Harris; O B Spiller; B P Morgan
Journal:  Immunology       Date:  2000-08       Impact factor: 7.397

6.  Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients.

Authors:  Elaine M Sloand; Loretta Pfannes; Phillip Scheinberg; Kenneth More; Colin O Wu; McDonald Horne; Neal S Young
Journal:  Exp Hematol       Date:  2008-10-26       Impact factor: 3.084

7.  Preterm labor: CD55 in maternal blood leukocytes.

Authors:  Stella Nowicki; Michael G Izban; Edyta Pawelczyk; Vincent K Agboto; Siddarth Pratap; Gayle Olson; Bogdan Nowicki
Journal:  Am J Reprod Immunol       Date:  2009-05       Impact factor: 3.886

Review 8.  Endothelial cells in allograft rejection.

Authors:  Rafia S Al-Lamki; John R Bradley; Jordan S Pober
Journal:  Transplantation       Date:  2008-11-27       Impact factor: 4.939

Review 9.  Complement-mediated injury and protection of endothelium: lessons from atypical haemolytic uraemic syndrome.

Authors:  Heather Kerr; Anna Richards
Journal:  Immunobiology       Date:  2011-07-30       Impact factor: 3.144

10.  Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from endothelial cells.

Authors:  L R Benzaquen; A Nicholson-Weller; J A Halperin
Journal:  J Exp Med       Date:  1994-03-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.